Concepedia

Jasmine Hewlett

JH

Statistics

Publications

5

Citations

1.1K

H-Index

5

Active since

1999

Affiliations

Alexion Pharmaceuticals (United States)(Current)

Fondazione IRCCS Istituto Neurologico Carlo Besta

University of North Carolina at Chapel Hill

Alnylam Pharmaceuticals (United States)

Wellcome Trust

Jasmine Hewlett is an author at Alexion Pharmaceuticals (United States) specializing in pharmacology, anti-acetylcholine receptor antibodies, and medicine.

Publications per year

1999–2020

5

Publications

5

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

James F. Howard, Kimiaki Utsugisawa, Michael Benatar et al. · The Lancet Neurology · 2017 · 800 citations

, , +6

Double‐Blind Placebo‐Controlled Study of Concurrent Administration of Albendazole and Praziquantel in Schoolchildren with Schistosomiasis and Geohelminths

G R Olds, Charles H. King, Jasmine Hewlett et al. · The Journal of Infectious Diseases · 1999 · 156 citations · Full text

, , +17

Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension

Renato Mantegazza, Gil I. Wolfe, Srikanth Muppidi et al. · Neurology · 2020 · 79 citations · Full text

, , +9

Eculizumab improves fatigue in refractory generalized myasthenia gravis

Henning Andersen, Renato Mantegazza, Jing Jing Wang et al. · Quality of Life Research · 2019 · 56 citations · Full text

, , +14

Response to eculizumab in patients with myasthenia gravis recently treated with chronic IVIg: a subgroup analysis of REGAIN and its open-label extension study

Saiju Jacob, Hiroyuki Murai, Kimiaki Utsugisawa et al. · Therapeutic Advances in Neurological Disorders · 2020 · 26 citations · Full text

, , +13

1–5 of 5